COMPARE · Data as of August 21, 2026
AUPH vs PTCT
Verdict: Side-by-side breakdown using the Bull Rankings model. AUPH scored 72.6, PTCT scored 24.7 — AUPH leads.
Compare another set
AUPH
Aurinia Pharmaceuticals Inc.
72.6
$16.65 · $2.2B
fundamentals as of
Score gap
47.9
AUPH leads
PTCT
PTC Therapeutics, Inc.
24.7
$69.82 · $5.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthAUPH+20.4%
- Highest qualityAUPH74 / 100
- Largest discount to fair valueAUPH-9%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
AUPH
stronger →← stronger
PTCT
74
Qualityreturns · margins · balance sheet
39
60
Growthrevenue & earnings expansion
15
86
Valuevaluation vs sector peers
26
AUPH is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
AUPH
PTCT
$175mC
FCF
-$40mF
+20.4%A-
Rev
-42.8%F
0.10B+
D/E
—
7.3xA
P/E
—
0.58A-
PEG
—
—
P/S
5.8xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AUPH
PTCT
9% below
Price vs fair valuelower is cheaper
—
~6%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-3%
1-yr DCF upside
—
+10%
5-yr DCF upside
—
+30%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AUPH
Why this score
- Earnings outpace cash
PTCT
Why this score
- Diluting shareholders
The companies
AUPHAurinia Pharmaceuticals Inc.
Why now
Biotechnology · market cap $2.2b. 14% off the 52-week high of $19.25. Revenue growing +20%, comfortably above the S&P median. PEG 0.58 — paying under fair value for the growth rate. 6 sell-side analysts rate this a Buy with a mean 1-yr target of $18.17 (implying +9% upside).
Moat
ROE 51% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.40 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
PTCTPTC Therapeutics, Inc.
Why now
Biotechnology · market cap $5.8b. Down 23% from 52-week high of $90.87 — deep drawdown territory. Revenue -43% — in contraction; any catalyst that reverses this triggers re-rating. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $99.29 (implying +42% upside).
Moat
ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AUPH and PTCT diverge
On the headline score the gap is 47.9 points in favor of AUPH. The widest single difference is Value, where AUPH leads by 59.7 points.
- ValueAUPH 85.7 · PTCT 26.0AUPH +59.7
- GrowthAUPH 60.3 · PTCT 14.7AUPH +45.6
- QualityAUPH 74.0 · PTCT 39.2AUPH +34.8
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.